Preliminary tests reveal no significant changes in the pandemic (H1N1) 2009 virus based on investigations of samples taken from patients in Ukraine. Analyses are being performed by two WHO influenza collaborating centres as part of the global influenza surveillance network.
2009 Nov - Clinical management of human infection with pandemic influenza (H1N1) 2009: revised guidance. Geneva: World Health Organization; 2009 Nov.
WHO revised its guidance on clinical management of pandemic influenza (H1N1) infection.
This document was developed by the Royal College of Paediatrics and Child Health with support from the Health Protection Agency and the Department of Health and has been approved by: the Association of Paediatric Anaesthetists, Great Britain and Ireland; the Intensive Care Society; the Paediatric Intensive Care Society; and the Royal College of Anaesthetists.
2009 Oct 23 - FDA Authorizes Emergency Use of Intravenous Antiviral Peramivir for 2009 H1N1 Influenza for Certain Patients, Settings
FDA: For Immediate Release: Oct. 23, 2009
The U.S. Food and Drug Administration announced today that, in response to a request from the U.S. Centers for Disease Control and Prevention, it has issued an emergency use authorization (EUA) for the investigational antiviral drug peramivir intravenous (IV) in certain adult and pediatric patients with confirmed or suspected 2009 H1N1 influenza infection who are admitted to a hospital.
Stockholm, Sweden, 5 Oct 2009
Americans Elizabeth H. Blackburn, Carol W. Greider and Jack W. Szostak won the 2009 Nobel Prize in Physiology or Medicine for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase.
Press release summary: This year's Nobel Prize in Physiology or Medicine is awarded to three scientists who have solved a major problem in biology: how the chromosomes can be copied in a complete way during cell divisions and how they are protected against degradation. The Nobel Laureates have shown that the solution is to be found in the ends of the chromosomes – the telomeres – and in an enzyme that forms them – telomerase.
Published: Tuesday, July 21, 2009 12:26 AEST
Expires: Monday, October 19, 2009 12:26 AEST
Critically ill patients with swine flu can now be treated on location with the New South Wales Government ordering special transportable respirators.
Click Read More to listen to a news clip about the experience of using ECMO for human swine flu at the St. Vincent's Hospital, Australia.
The treatment received by Sharon Pentleton, who is pregnant, saves one life for every six, says the study
Patients with swine flu who experience severe respiratory failure should be given a specialist lung treatment, researchers say today.
..... In Leicester, of 13 swine flu patients treated so far with ECMO, 85 per cent have survived. .....
Fergus Walsh speaks to Richard Firmin at the ECMO unit at Glenfield Hospital in Leicester about how the lung bypass machines have been used in Australia and how they can help patients with very severe lung illness to recover.
Click Read More to go to BBC to watch the video.
Youtube link: Video Report by Dr Giles Peek at the 37th SCCM Critical Care Conference at Honolulu in 2008
Click READ MORE to go to the Trial Website.
2009 Sep 15 - New York Times: Machine for Breathing Troubles May Aid in Swine Flu Care, Researchers Say
In a study with implications for swine flu treatment, British researchers have found that some patients with severe breathing problems do better if their blood is run through a heart-lung machine than if they are attached to a conventional ventilator. ..... “We have already used ECMO during the first wave of the pandemic with good effect, ....
This document is published by NHS which describes the approach to manage critical care needs in a H1N1 influenza pandemic, including to prevent people becoming seriously ill as a result of H1N1 influenza and to increase intensive care capacity.
2009 Aug 20 - WHO Guidelines for Pharmacological Management of Pandemic (H1N1) 2009 Influenza and other Influenza Viruses
The purpose of this document is to provide a basis for advice to clinicians on the use of the currently available antivirals for patients presenting with illness due to influenza virus infection as well the potential use of the medicines for chemoprophylaxis. The document addresses specifically the two neuraminidase inhibitors oseltamivir and zanamivir, and the two M2 inhibitors amantadine and rimantadine. It includes recommendations on the use of some other potential pharmacological treatments.
This September issue of the Hong Kong Medical Diary on Intensive Care represents the very first time the Medical Diary has incorporated Intensive Care into the list of medical topics to be shared with Diary readers. The breadth of mind of the Diary Editors for entertaining non-traditional medical subjects such as Intensive Care and the boldness in committing one whole issue to this subject are much to be congratulated on for making this issue possible. Much gratitude goes to the current and former Editors-in-Chief, Drs Chun-on Mok and Walter King, for their kind encouragement and support. Much gratitude also goes to the esteemed authors of this issue, who, based on their vast experience in managing the critically ill in the intensive care unit (ICU), have together produced this very handsome issue on Intensive Care.
SCMP: A resident of a home for the disabled in Shau Kei Wan is the first local resident with human swine flu that is resistant to Tamiflu, ...... The case is just the seventh in the world, .....
This practice note is presented to clinical colleagues to assist the management of cases of A(H1N1). The recommendations are based primarily on adult ICU practice and arise from the international H1N1 ICU network teleconferences held since 5 June 2009, with the most recent occurring on 22 July 2009.
FDA ALERT [06/03/2009]
FDA is notifying healthcare professionals of the risk of serious liver injury, including liver failure and death, with the use of propylthiouracil (PTU) in adult and pediatric patients.
Reports to FDA’s Adverse Event Reporting System (AERS) suggest there is an increased risk of hepatotoxicity with PTU when compared to methimazole (MMI). Although both PTU and MMI are indicated for the treatment of hyperthyroidism due to Graves’ disease, healthcare professionals should carefully consider which drug to initiate in a patient recently diagnosed with Graves’ disease. Physicians should closely monitor patients on PTU therapy for symptoms and signs of liver injury, especially during the first six months after initiation of therapy. PTU and MMI were approved in 1947 and 1950, respectively.